A CARVED FIELD RECORD / TWO PEPTIDES, ONE REPAIR SIGNAL
BPC-157 TB-500 is a two-peptide research blend traced through the tissue-repair literature.
Two structurally unrelated peptides — a local cytoprotective signal and a cytoskeletal cell-migration signal — read against their own studies, with the combination gauge left honestly at no signal.
Two peptides, one carved record
BPC-157 TB-500 is the research-community name for a pairing of two distinct synthetic peptides marketed and discussed as a tissue-repair "stack." It is not a single chemical entity: it has no shared molecular weight, no CAS number, and no standardized ratio. The first peptide, BPC-157, is a 15-amino-acid pentadecapeptide derived from a protein found in human gastric juice. The second, TB-500, is a synthetic seven-amino-acid acetylated fragment of the much larger protein Thymosin Beta-4.
The two are paired because their proposed mechanisms are complementary. BPC-157 supplies a local cytoprotective and pro-angiogenic signal, up-regulating VEGFR2 with downstream Akt-eNOS activation [2]. TB-500 supplies an intracellular actin-sequestration signal: its LKKTETQ motif binds monomeric G-actin in a 1:1 complex, the structural basis for regulating cell migration [3]. These pathways are largely non-overlapping, and that separation is the entire basis of the "synergy" claim.
This site is a carved field record of that literature — each finding logged to its source, each peptide marked to the studies it actually derives from. It does not sell, prescribe, or supply anything. For the regulatory picture, see Wolverine legal status and FDA 503A category.
Why BPC-157 and TB-500 are combined
The pairing rationale is mechanistic complementarity, not a measured combined result. BPC-157's local angiogenic and cytoprotective signal is proposed to cover the vascular and survival side of repair, while TB-500's cytoskeletal cell-migration signal is proposed to cover the cell-movement side. The two are presented as addressing different stages of tissue repair through different molecular routes.
The critical caveat is unmissable: no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint for the two given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine surveyed 36 studies and made no mention of TB-500 or any combination [9]. "Synergy" here is an extrapolation from each peptide's separately characterized mechanism — a hypothesis the published record has not tested. See why BPC-157 and TB-500 are combined for the full mechanism discussion.
What the blend is studied for
All efficacy data sit at the level of the individual constituents, in animal models. For BPC-157, the flagship result is tendon repair: in fully transected rat Achilles tendons, BPC-157 improved healing across biomechanical, functional, microscopic, and macroscopic measures, and in cultured tendocytes reversed growth inhibition into stimulation [1]. At the cellular level, BPC-157 enhanced tendon-fibroblast outgrowth, survival, and migration through FAK-paxillin signaling [7], and up-regulated the growth-hormone receptor in tendon fibroblasts [5].
For TB-500, the consolidated mechanism comes from its parent protein. A review of Thymosin Beta-4 describes actin binding, cell mobilization and migration, reduced myofibroblast number (less scarring), anti-inflammatory activity, and angiogenesis [4]. These are single-compound, mostly rodent findings. The blend itself has no controlled efficacy study, and most data attributed to "TB-500" were generated with full-length Thymosin Beta-4, not the seven-amino-acid fragment that is actually sold.
Reading the record honestly
The evidence for both constituents is overwhelmingly preclinical. BPC-157 has only three small human pilot studies; the TB-500 fragment has zero completed controlled human trials, with the human data attributed to it coming from the full-length protein. Recent reviews call BPC-157 investigational and note that rigorous large-scale trials are lacking [11].
Neither constituent is an approved drug. A 2026 narrative review of approved and unapproved musculoskeletal peptides — listing both BPC-157 and Thymosin Beta-4 — concluded that many show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [10]. The honest position is that the combination's human efficacy and safety are unproven, and the BPC-157 and TB-500 research findings here are reported as research, not as outcomes a reader should expect.
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a human gastric-juice protein. TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region, residues 17-23, of Thymosin Beta-4. The "Wolverine" blend pairs the two as a research-community tissue-repair stack [3].
What Is the Wolverine Peptide Blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or standardized ratio, and is not an approved product anywhere [4].
What the Blend Is Studied For
Preclinical, mostly rodent research on the two constituents covers tendon, ligament, muscle, and bone repair, wound and soft-tissue healing, cytoprotection, and angiogenesis. These are single-compound, animal-model findings; the blend itself has no controlled efficacy study [1].
Why BPC-157 and TB-500 Are Combined
The rationale is complementary mechanisms: BPC-157's local cytoprotective and angiogenic signal (VEGFR2-Akt-eNOS) is paired with TB-500's cytoskeletal cell-migration signal, so the two are proposed to cover different stages of tissue repair [2]. Critically, no head-to-head or combination study has defined a synergistic dose, ratio, or endpoint [9].
BPC-157 vs TB-500: Two Distinct Compounds
They are structurally unrelated. BPC-157 is a 15-amino-acid pentadecapeptide (~1419.5 Da) from a gastric-juice protein acting via VEGFR2/eNOS angiogenic and growth-hormone-receptor pathways [2]. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of Thymosin Beta-4 that sequesters G-actin to regulate cell migration [3]. Different sequences, sizes, and mechanisms.
BPC-157 TB-500 Stack (Wolverine)
The community "stack" is the same two-peptide pairing under a different name. There is no validated stack dose, ratio, or schedule, and no combination trial behind the term — the synergy framing is theoretical, drawn from each peptide's separate mechanism [9].
BPC 157 TB 500 (Unhyphenated)
The unhyphenated spelling BPC 157 TB 500 refers to the identical two-peptide blend; the spacing is a search-surface variant, not a different product [3].
Why the Research Community Pairs BPC-157 with TB-500
The research community pairs BPC-157 with TB-500 because their characterized mechanisms are complementary and non-overlapping — a local angiogenic-cytoprotective signal alongside a cytoskeletal migration signal [2]. No controlled combination study has demonstrated that pairing them produces a greater-than-additive effect [9].